CDK4 and neoplasm: Recent work by the Ruscetti group highlights how the combination of CDK4/6 and MEK inhibitors synergistically and favorably alters the tumor microenvironment of Ras-driven lung cancer and pancreatic ductal adenocarcinoma (PDAC).